2025 State PANS and PANDAS Legislation

		Johnson Policy Consulting	
Jurisdiction	Bill Number	Description	Status
Arkansas	SB 128	Appropriates \$175,000 to the University of Arkansas for Medical Sciences PANS/PANDAS Clinic and Programs for fiscal year ending June 30, 2026.	4/10/2025 SB128 is now Act 533.
Arkansas	HB 1573	Amends the statute pertaining to the Arkansas Interdisciplinary Council for Medical Sciences concerning a protocol to be developed for the diagnosis and treatment for PANDAS.	4/15/2025 Recommended for study in the Interim by the Committee on House Rules.
Georgia	HB 878	Designates October 9th of each year as PANDAS Day in Georgia.	4/2/2025 House Second Readers. Carry over to 2026.
Georgia	HB 124	Requires all health benefit policies issued or renewed after July 1, 2025, including individual and group health benefit plans and health care services contracts, to cover health care services for PANS and PANDAS. Coverage must include services for the diagnosis, treatment, appropriate management or ongoing monitoring of a covered person's disorder when such services are supported by nationally recognized clinical practice guidelines. Beginning January 1, 2026 and the state health benefit plan for employees is required to provide the same coverage.	2/26/2025 To Senate Insurance and Labor Committee. Carry over to 2026.
Georgia	HR 778	Recognizes October 9, 2025, as PANDAS Awareness Day at the state capitol.	3/27/2025 House read and adopted.
Georgia	SB 5, substituted version	Bill substitute to include language related to PANS and PANDAS. Requires individual and group health benefit plans, health care services contracts, and the state health benefit plan for employees to cover health care services for PANS and PANDAS. Coverage must include services for the diagnosis, treatment, appropriate management or ongoing monitoring of a covered person's disorder when such services are supported by nationally recognized clinical practice guidelines.	5/14/2025 Signed by the Governor. Act 299. Effective 7/1/2025.
Georgia	SB 205	Requires individual and group health benefit plans, health care services contracts, and the state health benefit plan for employees to cover health care services for PANS and PANDAS. Coverage must include services for the diagnosis, treatment, appropriate management or ongoing monitoring of a covered person's disorder when such services are supported by nationally recognized clinical practice guidelines.	2/20/2025 Senate Read and Referred. Carry over to 2026.
lowa	SF 242	Requires a health carrier that offers individual, group or small contracts, policies or plans that provide third party payment or prepayment of health and medical expenses to offer coverage for the diagnosis and treatment of PANS, PANDAS and postinfectious autoimmune encephalopathy recommended by a covered person's health care professional as medically necessary. Treatment may include but is not limited to antibiotics, drugs, and behavioral therapies to manage behavioral symptoms, plasma exchange, and immunoglobulin. Coverage may not (1) be denied or delayed because an individual has received the same or similar prior treatment for the condition; (2) be denied or delayed because the covered person receives treatment for another medical condition; (3) limited over a covered person's lifetime unless limited by a policy period or because a person's health care provider has determined that the patient is no longer benefitting from the treatment. Covered entities include individual and group accident and sickness insurance providing coverage on an expense-incurred basis, individual or group hospital or medical service contracts, individual and group HMOs and a plan established for public employees.	2/17/2025 Subcommittee recommends passage. Session adjourned. Carry over to 2026.

		Johnson Policy Consulting	
Jurisdiction	Bill Number	Description	Status
Louisiana	HB 408	Requires that every health coverage plan renewed, delivered, or issued for delivery must provide coverage for the treatment of PANS and PANDAS, including intravenous immunoglobulin. Insurers may consider but not require strict adherence to other treatment options or recommendations developed by a medical professional consortium convened for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of these disorders, such as the PANDAS Physician Network. The treatment should be based on evidence of positive patient outcomes. A health coverage plan may limit intravenous immunoglobulin treatments to no more than three monthly courses of treatment, unless additional treatment is deemed medically necessary based on a clinical review using such guidelines.	2025-06-20 Signed by the Governor. Becomes Act No. 360. Effective 8/1/2025.
Massachusetts	<u>S 1415</u>	Requires the Department of Mental Health, in conjunction with the Department of Education to conduct a study of pediatric and adolescent psychiatric hospital settings and therapeutic day schools to determine if any children within these settings have root causes in missed or known neuroimmune issues or PANS and PANDAS. The study findings must include information regarding prevalence and report outcomes of interviewed children & families previously misdiagnosed and subsequently found to have PANS and PANDAS.	6/24/25 Hearing held on 06/30/2025. Joint Mental Health, Substance Abuse and Recovery Committee.
Massachusetts	<u>S 805</u>	Requires the department of public health to establish a program for PANS and PANDAS screening, which must adhere to the recommendations developed by a medical professional consortium convened by the department for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of such disorders or syndrome that are accessible for medical professionals and are based on evidence of positive patient outcomes. The department also must develop PANS working criteria to describe a clinically distinct presentation as defined in legislation. Physicians, licensed child psychiatrists or psychologists, licensed certified social workers and licensed mental health counselors must screen patients for PANS and PANDAS using specified methods. Licensed, registered or approved health care facilities serving children, including but not limited to hospitals, clinics and HMOs must take appropriate steps to ensure that their patients receive specified PANS and PANDAS screening.	2/27/2025 In Senate. Referred to Committee on Financial Services.
Massachusetts	H 1249	Requires the department of public health to establish a program for PANS and PANDAS screening, which must adhere to the recommendations developed by a medical professional consortium convened by the department for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of such disorders or syndrome that are accessible for medical professionals and are based on evidence of positive patient outcomes. The department also must develop PANS working criteria to describe a clinically distinct presentation as defined in legislation. Physicians, licensed child psychiatrists or psychologists, licensed certified social workers and licensed mental health counselors must screen patients for PANS and PANDAS using specified methods. Licensed, registered or approved health care facilities serving children, including but not limited to hospitals, clinics and HMOs must take appropriate steps to ensure that their patients receive specified PANS and PANDAS screening.	2/27/2025 In House. Referred to the Committee on Financial Services.
Michigan	SB 447	Health insurance policies and health insurance policies delivered, executed, issued, amended, adjusted, or renewed in Michigan must provide coverage for the prophylaxis, diagnosis, and treatment of PANDAS and PANS that is prescribed or ordered by a physician or provider, including, but not limited to, antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and the use of intravenous immunoglobulin therapy. Requires that treatment authorization is in a timely manner. Treatment may not be delayed or denied based on the insured previously receiving any treatment, including the same or similar. Insurers must adhere to treatment recommendations developed by a medical professional consortium convened for the purposes of researching, identifying, and publishing clinical practice guidelines and evidence-based standards for prophylaxis, diagnosis, and treatment of the disorders.	6/26/2025 Referred to Committee on Health Policy.
Missouri	HB 623	Designates March 26th of each year as PANS/PANDAS Awareness Day.	05/15/2025 Referred: Emerging Issues (H) Died.

		Johnson Policy Consulting	
Jurisdiction	Bill Number	Description	Status
New Jersey	A 5325	Requires hospital and medical service corporations, health service corporation contracts. Individual and group health insurance policies, individual health benefit plans, small employer health benefit plans, HMOs, The State Health Benefits Commission, and the School Employees Health Benefits Commission to cover expenses incurred in the diagnosis and treatment of PANDAS and PANS that is prescribed or ordered by the treating physician. Coverage must include, but is not limited to, antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.	2/20/2025 Introduced, Referred to Assembly Financial Institutions and Insurance Committee.
New Jersey	<u>S 4444</u>	Requires hospital and medical service corporations, health service corporation contracts. Individual and group health insurance policies, individual health benefit plans, small employer health benefit plans, HMOs, The State Health Benefits Commission, and the School Employees Health Benefits Commission to cover expenses incurred in the diagnosis and treatment of PANDAS and PANS that is prescribed or ordered by the treating physician. Coverage must include, but is not limited to, antibiotics, medication and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy.	5/19/2025 To Senate Commerce Committee.
New York	<u>S 2655</u>	Requires health plans and health issuers offering health insurance coverage as a group health plan to provide coverage for a beneficiary or participant who has PANS if the attending physician certifies in writing the medical necessity of the proposed course of rehabilitative treatment.	1/22/2025 Referred to Insurance Committee
New York	A 3362	Requires health plans and health issuers offering health insurance coverage as a group health plan to provide coverage for a beneficiary or participant who has PANS if the attending physician certifies in writing the medical necessity of the proposed course of rehabilitative treatment.	1/27/2025 Referred to Insurance Committee.
Rhode Island	H 5625	Eliminates (1) the sunset provision of all statutes requiring coverage for the treatment of PANS and PANDAS; (2) provisions regarding coding; and (3) section requiring a cost benefit analysis due Jan. 1, 2025.	6/27/2025 Signed by the Governor.
Rhode Island	<u>S 473</u>	Eliminates (1) the sunset provision of all statutes requiring coverage for the treatment of PANS and PANDAS; (2) provisions regarding coding; and (3) section requiring a cost benefit analysis due Jan. 1, 2025.	6/27/2025 Signed by the Governor.
Tennessee	HB 411	The Division of TennCare must require group health insurance contracts, group or hospital medical insurance policies, plans or group policies delivered, issued, amended or renewed by a managed care organization to cover medically necessary prescribed treatment for PANS and PANDAS. Treatment includes antibiotics, medication, behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunologlobulin therapy. A group or individual health insurance policy may not deny or delay coverage of medically necessary treatment solely on the basis of prior treatment for PANS and PANDAS. Coverage for PANS and PANDAS treatment must adhere to the treatment recommendations developed by a medical professional consortium. Requires the use of the diagnostic code for autoimmune encephalitis for billing purposes in the absence of a code for PANS and PANDAS.	5/27/2025 Signed by the Governor. Effective date 05/21/2025.
Tennessee	<u>SB 1426</u>	The Division of TennCare must require group health insurance contracts, group or hospital medical insurance policies, plans or group policies delivered, issued, amended or renewed by a managed care organization to cover medically necessary prescribed treatment for PANS and PANDAS. Treatment includes antibiotics, medication, behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunologlobulin therapy. A group or individual health insurance policy may not deny or delay coverage of medically necessary treatment solely on the basis of prior treatment for PANS and PANDAS. Coverage for PANS and PANDAS treatment must adhere to the treatment recommendations developed by a medical professional consortium. Requires the use of the diagnostic code for autoimmune encephalitis for billing purposes in the absence of a code for PANS and PANDAS.	4/27/2025 Comp. became Pub. Ch. 482. (companion bill to TN HB 411)

		Johnson Policy Consulting	
Jurisdiction	Bill Number	Description	Status
Tennessee	HJR 73	Commemorates October 9, 2025 as PANDAS Awareness Day.	3/12/2025 Signed by the Governor.
Virginia	HB 1641	Authorizes the Board of Medical Assistance Services to amend the state plan for medical assistance services to include a provision for payment for the prophylaxis, diagnosis, and treatment of PANDAS and PANS. Requires individual and group accident and sickness insurers; corporations providing individual or group accident and sickness subscription contracts; and health maintenance organizations providing a health care plan for health care services to cover prophylaxis, diagnosis, and treatment of PANDAS and PANS. Coverage requirements include antimicrobials, medication, and behavioral therapies to manage neuropsychiatric symptoms, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy. Prohibits certain actions with respect to coverage determinations.	3/18/25 Acts of Assembly Chapter text (CHAP0008)
Virginia	SJR 273	Appoints Ann Flippin, David Jaffe, Aradhana Sood and Terry Woody to the Advisory Council on PANDAS and PANS.	2/7/2025 Bill text as passed Senate and House (SJ273ER)
Virginia	SJR 274	Appoints Brian Gottstein, Galam Khan, and Kristina Nunnally to the Advisory Council on PANDAS and PANS.	2/7/2025 Bill text as passed Senate and House (SJ274ER)
Virginia	SJR 275	Appoints Susan Swedo to the Advisory Council on PANDAS and PANS.	2/7/2025 Bill text as passed Senate and House (SJ275ER).
Washington	HB 1198	The State Health Care Authority must consider evidence-based recommendations from the Oregon health evidence review commission when making coverage decisions for the treatment of PANDAS and PANS. Provision is within appropriations bill.	4/1/2025 To House Rules Committee. Session adjourned. No carryover of appropriations bill.
Washington	<u>SB 5167</u>	The State Health Care Authority must consider evidence-based recommendations from the Oregon health evidence review commission when making coverage decisions for the treatment of PANDAS and PANS. Provision is within appropriations bill.	Effective date 5/20/2025. (Partial veto by Governor does not include this provision).
Washington	HB 1741	For health plans other than those offered to public employees and dependents, health carriers must provide initial coverage for three monthly immunomodulatory courses of intravenous immunoglobulin for the treatment of PANDAS and PANS and subsequent courses as deemed necessary by treating providers when certain conditions are met. Conditions include consultation with a subspecialist and that the subspecialist and primary care provider recommend the treatment. The health carrier may require that the patient be clinically reevaluated every three months.	1/30/2025 First reading, referred to Health Care & Wellness. Carry over to 2026.
West Virginia	<u>SB 297</u>	The West Virginia Public Employees Insurance Plan, Medicaid, individual and group accident and sickness insurance, hospital and medical service corporations, health service corporations, health care corporations, and HMOs shall only cover intravenous immunoglobulin therapy for PANDAS, PANS and other autoimmune encephalopathies if the insured's physician obtains prior authorization by showing that all other treatments have been exhausted.	3/12/2025 To Senate Finance. Carries over to 2026 session if requested by sponsor.
Updated 7/16/2025		Johnson Policy Consulting https://policyconsult.com/resources	202-258-5529